Clinical TrialsThe findings are encouraging for the Bria-IMT + CPI combination therapy as it progresses in Phase 3 trials.
Market ExpectationsThe reverse stock split and model update led to an increased price target of $32, showing improved market expectations for the stock.
Product SafetyThe overall safety profile of Bria-IMT was found to be positive, with the treatment regimen being well tolerated, with no patient discontinuations.